Life science platform company VION Biosciences has acquired BioAssay Systems, a San Francisco area-based biotechnology company and enzymatic assay innovator.
BioAssay Systems specialises in high-throughput assay solutions for life science research and drug discovery.
This acquisition is VION Biosciences’ fourth investment, expanding its portfolio of proprietary products in life science research, diagnostics, and drug discovery.
The deal will help the life science platform firm provide a reliable solution to companies and organisations performing critical research in the life science space.
It also strengthens VION Biosciences’ position in drug discovery and research and enhances its proprietary product offering in a competitive research market.
VION Biosciences CEO Mark Thornton said: “Welcoming BioAssay Systems and its talented team of scientists into the VION portfolio marks an exciting next step in our company’s growth.
“Bioassay’s biochemical and enzyme-mediated assay toolbox will complement VION’s growing portfolio of assays that enable rapid testing for drug discovery across multiple areas of disease research including metabolic disorders, obesity, and oncology.
“By combining forces, we are expanding our capabilities while also giving scientists the tools they need to accelerate breakthroughs.”
VION Biosciences has completed four acquisitions, all proprietary in nature. These include Aldon in 2023, and Echelon Biosciences and Ansh Labs in 2024.
The life science platform company said each acquisition strengthens its platform, designed to support the life science industry with high-performance products.
These deals will also support VION Biosciences’ expansion efforts to evolve its speciality products platform, with BioAssay Systems already commercialising globally.
BioAssay Systems will continue to be led by Frank Huang and will operate from Hayward, California. As a subsidiary of the VION Biosciences, it will continue serving existing customers while integrating into the infrastructure of the life science platform company.
This year, the company will strengthen BioAssay Systems’ team with additional leadership and resources as the company expands.
McDermott Will & Emery is serving as VION Biosciences’ legal adviser, while Kroll is acting as its financial adviser.
